好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Optical Coherence Tomography Angiography (OCTA) Retinal Imaging Can Detect Burden of Small Vessel Disease and Amyloid Deposition in the Brain
Cerebrovascular Disease and Interventional Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
6-001

To investigate the utility of retinal imaging with optical coherence tomography angiography (OCTA) metrics as noninvasive biomarkers of small vessel disease and amyloid burden in the brain.

OCTA allows visualization and density measurements of the capillaries at various levels of the retina. Vascular changes and amyloid deposition associated with Alzheimer’s Disease (AD) and other dementias may be reflected as density changes in the retinal capillaries, making OCTA a noninvasive preclinical biomarker of small vessel disease and dementia.

We investigated associations between OCTA and neuroimaging metrics in 47 cognitively unimpaired participants from the Mayo Clinic Study of Aging. OCTA metrics were used as predictors and included superficial and deep capillary density of the fovea, parafovea, and macula as well as the foveal avascular zone (FAZ) area from both eyes. Neuroimaging metrics included a high burden of white matter hyperintensity (WMH), presence of cerebral microbleeds, presence of lacunar infarcts, and the presence of amyloid deposition as evidenced on positron emission tomography (PET).  We used linear models to test associations between OCT predictors and neuroimaging outcomes while controlling for age and sex.

Associations between neuroimaging metrics were restricted to the fovea, showing decreased capillary density with increased burden of WMH in both the superficial (p = 0.014) and deep (p = 0.013) fovea but not the parafovea or whole macula. Similarly, participants with amyloid deposition had decreased capillary density in the superficial (p=0.012) and deep (p = 0.015) fovea but not the parafovea or macula. Participants with amyloid deposition also had a significantly larger FAZ (p = 0.029). No associations were found between OCT metrics and presence of cerebral microbleeds or presence of lacunar infarcts.

The foveal capillary density associations observed suggest a possible common mechanism of disease between small vessel disease and Alzheimer’s disease pathologies.  

Authors/Disclosures
Camilo Bermudez, MD, PhD (Mayo Clinic)
PRESENTER
Dr. Bermudez has nothing to disclose.
Timothy Lesnick No disclosure on file
No disclosure on file
Vijay K. Ramanan, MD, PhD (Mayo Clinic) The institution of Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daridorexant trial for AD prevention (funded by Weston Family Foundation). The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. The institution of Dr. Ramanan has received research support from Roche/ADLM. The institution of Dr. Ramanan has received research support from American College of Radiology. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Speaker/CME Content with Clinical Care Options.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .
John Chen John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.